X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration between Lupus Therapeutics and AbbVie will tap into the expertise of clinical researchers in the Lupus Clinical Investigators Network to help facilitate and improve the clinical trial process in the evaluation of Rinvoq (upadacitinib) in SLE.
Lead Product(s): Upadacitinib
Therapeutic Area: Immunology Product Name: Rinvoq
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 24, 2023
Details:
Under the agreement, Lupus will help Novartis to conduct three Phase 3 clinical trials testing an investigational therapeutic VAY736 (ianalumab), a monoclonal antibody, targeting BAFF-R, for systemic lupus erythematosus and lupus nephritis.
Lead Product(s): Ianalumab
Therapeutic Area: Nephrology Product Name: VAY736
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 02, 2023
Details:
The study in collaboration with Lupus Therapeutics' Lupus Clinical Investigators Network (LuCIN), will assess the potential benefit of hydroxychloroquine in lupus COVID-19 patients.
Lead Product(s): Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
